Taking lead in breast cancer research

Share this article

We are delighted that Professor Mike Dixon, one of the UK’s top breast surgeons based at the Western General Hospital in Edinburgh, has received an OBE for services to the treatment of breast cancer and for charitable activity.

Professor Dixon, breast surgeon and clinical lead of the Breakthrough Breast Cancer research at the Western General Hospital treats women with breast cancer across the Lothians, Fife and the Scottish Borders.

His commitment to charities such as Breakthrough Breast Cancer is amazing, not just leading research projects but raising tens of thousands of pounds too.

Each year Professor Dixon rallies a strong team of challengers called “Mike’s Marvels” to join him in a physical activity challenge. This year, Professor Dixon is, again, going the extra mile by taking part in Pedal for Scotland in September.

If breast cancer has touched your life in any way please join the team by contacting our Edinburgh office on 0131 226 0761.

In addition to his fundraising efforts, he has made a remarkable contribution to the treatment of women with breast cancer and he has also furthered our understanding of the disease not just in Scotland but across the UK.

At Breakthrough we have recently committed to further Professor Dixon’s research programme in Edinburgh.

Over the next five years, Professor Dixon and his team will continue their work on the clinical effect of risk factors, drugs and drug resistance on a certain type of breast cancer, with the ultimate aim being to develop tests that will predict whether or not a patient will respond to treatment or will become resistant to it.

Breakthrough need to raise £425,000 over the next 5 years to fund this work.

Professor Dixon’s research and fundraising is not only changing the lives of women affected by breast cancer, but also helping us take vital steps towards our vision of a world freed from the disease. Please do support us.

James Jopling is Director for Scotland at Breakthrough Breast Cancer.